Navigation Links
AbbVie Reports Third-Quarter 2013 Financial Results
Date:10/25/2013

5)

n/a

n/a

(69.5)

(69.5)Duodopa

--

129

129

n/a

16.6

19.4

16.6

19.4Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations.
n/a = not applicable  AbbVie Inc.
Consolidated Statements of Earnings
Quarter and Nine Months Ended September 30, 2013 and 2012
(Unaudited) (In millions, except per share data)Third Quarter Ended September 30Nine Months Ended
September 302013201220132012Net sales

$4,658$4,508$13,679$13,174Cost of products sold

1,0921,0143,2993,243Selling, general and administrative

1,2611,0853,9043,578Research and development

7148132,0572,097Acquired in-process research and development

220--290260Total operating cost and expenses

3,2872,9129,5509,178Operating earnings

1,3711,5964,1293,996Interest (income) expense, net

69(1)210(4)Net foreign exchange (gain) loss

1164027Other (income) expense, net

5(13)(14)(39)Earnings before income tax

1,2861,6043,8934,012Income tax expense

32219893277Net earnings

$964$1,585$3,000$3,735Diluted earnings per share

$0.60$1.01$1.86$2.37Average diluted shares outstanding1,6051,5771,6021,577Note: On Jan. 1, 2013, Abbott Laboratories distributed 1,577 million shares of AbbVie common stock to Abbott's shareholders in connection with the separation of AbbVie from Abbott. The computation of diluted earnings per share for the quarter and nine months ended Sept. 30, 2012 was calculated using the shares distributed on Jan. 1, 2013. AbbVie Inc.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
Quarter Ended September 30, 2013
(Unaudited) (In millions, except per share data)1. Specified items impacted results as follows:3Q13Earnings

DilutedPre-tax

After-tax

EPSAs
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. AbbVie Named a Science Top Employer
2. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
3. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
4. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
5. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
6. AbbVie Declares Quarterly Dividend
7. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
8. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
9. AbbVie to Participate in 2013 Jeffries Global Healthcare Conference
10. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
11. AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  CVS Caremark Corporation (NYSE: ... call on Tuesday, August 5, 2014, at 8:30 a.m. ... quarter 2014 financial results. An audio webcast ... the Investor Relations portion of the CVS Caremark website ... http://info.cvscaremark.com/investors . This webcast will be archived and ...
(Date:7/25/2014)... , July 25, 2014 Cardinal Health will ... pharmacies as winners of its prestigious Independent Pharmacy Best ... , one of the nation,s largest gatherings of independent ... – family-owned pharmacies from Ohio , ... – were selected for implementing exceptionally creative ...
(Date:7/25/2014)... , July 25, 2014 According ... Research "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, ... Size, Share, Growth, Trends and Forecast (Value and Volume), ... at USD 19.99 billion in 2012 and is expected ... to 2019 to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... Medical Technologies, Inc. (the "Company") (Nasdaq: CMED ... today announced the filing of its annual report on ... 2011 with the U.S. Securities and Exchange Commission (the ... financial statements for the fiscal year ended March 31, ...
... July 18, 2011 Scientists at Osel Inc ... have developed a new way to prevent HIV infection ... bacteria to block viral transmission. Bioengineered bacteria introduced into ... the transmission of simian HIV (SHIV) by nearly two ...
Cached Medicine Technology:China Medical Technologies Announces the Filing of its Annual Report on Form 20-F for the Fiscal Year Ended March 31, 2011 with the SEC 2Scientists Use Live Bacteria to Fight HIV 2Scientists Use Live Bacteria to Fight HIV 3
(Date:7/25/2014)... This is a professional and ... Galactooligosaccharides (GOS) industry in Global and China. ... industry, including definitions, applications and industry chain structure. ... are provided with a focus on history, developments, ... comparison between the international and Chinese situation is ...
(Date:7/25/2014)... 25, 2014 As thousands of transvaginal ... courts, Bernstein Liebhard LLP notes that the Food & ... consumer advocacy group, Public Citizen, to order a global ... dated May 1, 2014, and released to the public ... for a ban on the marketing of all surgical ...
(Date:7/25/2014)... (HealthDay --, Treatment for lymphoma may lower men,s fertility, ... lymphoma, which are cancers of the body,s white blood ... their reproductive years. For men, treatment for these cancers ... regain their fertility within two years of treatment, the ... possibility of this significant side effect before treatment begins. ...
(Date:7/25/2014)... announced the launch of its ASA Perioperative Surgical ... to improve the patient experience before, during and ... care organizations from across the country will participate ... first time at the ASA,s PSH Learning Collaborative ... PSH collaborative participants will create a network where ...
(Date:7/25/2014)... 25, 2014 The new report ... Feed, Pharmaceuticals and Others), by Type (Amylases, Cellulases, ... Geography - Global Trends & Forecasts to 2019", ... of the global Carbohydrase market with analysis of ... is segmented and values are forecasted on the ...
Breaking Medicine News(10 mins):Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 4Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4
... March 11 Eli Manning, NFL Most,Valuable Player ... Champions New,York Giants, will address a National Press ... new national challenge to encourage Americans to be,more ... on the President,s Council on,Physical Fitness and Sports, ...
... Robbins & Myers, Inc.,(NYSE: RBN ) announced ... 2008 financial results for the period ended February 29, ... live webcast of the conference,call will be held at ... Peter,C. Wallace, President and Chief Executive Officer, and Christopher ...
... Kimmel Cancer Center have teased out two distinct sets ... that there are two completely different kinds of the ... neck tumors caused by the human papillomavirus (HPV), a ... certain sexual behaviors and marijuana use, rather than tobacco ...
... ZMH; SWX: ZMH), a leader in the orthopaedics industry, announced,today ... -- March 18, 2008 -- Cowen,s 28th Annual Health ... Eastern Time -- March 19, 2008 -- Eleventh Annual ... Beach, Florida, 8:30 a.m. Eastern Time, Live webcasts of ...
... to Strengthen,Human Services, which is committed to ensuring ... providers, today unveiled its,campaign website, http://www.strengthenhumanservices.org ... that human services providers bring to,all corners of ... Senate 65, a bill that would,establish a fair ...
... better survival rates, but one expert urges caution ... semi-specialized or specialized hospitals improved survival time for ovarian ... study, the researchers examined data on 8,621 ovarian cancer ... Of those women, 40 percent were treated in general ...
Cached Medicine News:Health News:Researchers ID behavioral risk factors for head and neck cancers 2Health News:Researchers ID behavioral risk factors for head and neck cancers 3Health News:New Human Services Website Details Economic Importance of Providers, Warns of Looming Crisis if System is Not Fixed Immediately 2Health News:Specialized Care for Ovarian Cancer Improves Outcomes 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: